U.S. Infrastructure Stock News

Candel Therapeutics, Inc. reported second-quarter 2026 results, with net loss widening to US$38.91 million and basic and diluted loss per share from continuing operations at US$0.52, while first-half 2026 net loss reached US$47.77 million compared with net income in the prior-year period. The sharp shift from profitability to loss over six months highlights a significant change in Candel Therapeutics’ operating profile that investors will scrutinize closely. We will now examine how this...

The recent shareholder proposal targeting Darden Restaurants (DRI) board election policies has pushed governance to the forefront ahead of the company’s September 23 annual meeting and drawn fresh attention to the stock’s recent performance metrics. See our latest analysis for Darden Restaurants. Against this governance backdrop, Darden Restaurants’ recent share price performance has stayed in focus, with a 13.9% 1 month share price return and an 18.5% year to date share price return,...

In recent months, Rogers Corporation has outlined ongoing portfolio optimization efforts, including exploring the sale of underperforming legacy businesses and emphasizing organic growth over acquisitions to enhance earnings quality and financial flexibility. This shift in focus has drawn fresh investor attention because it highlights a cleaner, more focused business mix that could reshape how the company allocates capital and manages risk. We’ll now examine how Rogers’ renewed emphasis on...

Lithia Motors (LAD) is back in the spotlight after Lithia & Driveway secured a place on the Fortune Global 500 for the second year, moving to No. 426 and reinforcing its expanding automotive retail footprint. See our latest analysis for Lithia Motors. The Fortune Global 500 recognition arrives at a time when Lithia Motors’ share price has gained 14.25% over the past 30 days and 35.33% over 90 days, while its 1 year total shareholder return sits at 22.08%. This points to building momentum...

Agilent Technologies (A) is back in focus after being highlighted as a key supplier to the expanding cannabis testing services market, along with a favorable analyst rank that points to improving earnings expectations and renewed investor interest. See our latest analysis for Agilent Technologies. The recent focus on Agilent Technologies as a key provider to cannabis testing services has coincided with a 19.31% 1 month share price return and a 35.39% 90 day share price return. The 1 year...

Stoke Therapeutics recently reported that its Phase III EMPEROR trial of zorevunersen in Dravet syndrome exceeded its 150-patient enrollment goal, reaching 162 patients with no discontinuations so far, and outlined plans to start a rolling FDA New Drug Application in the first quarter of 2027 and complete it by the third quarter of 2027. This smoother-than-expected enrollment, together with the clean retention profile, may strengthen confidence in the trial’s execution as the company...

Einride stock jumped 5.4% to $6.04 after its half year 2026 report, even as the headline story remains the strain on the balance sheet. The company is still generating losses, with basic earnings per share for the period at 17.85 SEK in the red and trailing twelve month losses near 78.77 SEK per share. That sits against a rich 16.1x price to sales multiple and a cash runway flagged as under one year. For investors, today’s move is less about a clean turnaround and more about how long the...

How IDACORP Stock Has Been Performing IDACORP (IDA) has drawn investor attention after recent trading left the stock about 4% lower over the past month, while total return over the past year remains about 14%. See our latest analysis for IDACORP. At a latest share price of US$140.76, IDACORP has seen recent momentum cool, with the 30-day share price return down 4.3%, even as the 1-year total shareholder return sits at about 14%. This points to a stock where long-term holders have still been...

Canadian Solar (NasdaqGS:CSIQ) is back in focus after a key legal overhang was removed. A long running U.S. patent infringement dispute with Maxeon Solar has now been resolved fully in Canadian Solar's favor. See our latest analysis for Canadian Solar. The legal win arrives as Canadian Solar's share price reacts sharply in the short term, with a 1 day share price return of 7.06% and a 30 day share price return of 3.82%, while the year to date share price return is down 37.90% and the 3 year...

Acadia Realty Trust (AKR) drew investor attention after extending a US$75 million loan to BTF Whitestone LLC to acquire and redevelop the Whitestone Shopping Center in Queens, a grocery anchored retail property. See our latest analysis for Acadia Realty Trust. Over the past year, Acadia Realty Trust has combined relatively muted recent share price moves with stronger longer term outcomes, with a 1 year total shareholder return of 14.18% and a 3 year total shareholder return of 66.73%. The...

In recent months, Crown Castle has been contending with a higher-for-longer interest rate backdrop while restructuring its balance sheet and reducing debt, even as a bankruptcy claim tied to tenant DISH Wireless introduces additional uncertainty. This combination of financing pressures and customer-related legal risk directly affects how secure Crown Castle’s cash flows may appear to investors and lenders. Next, we’ll examine how the interest rate pressure and DISH-related bankruptcy...

AbCellera Biologics (ABCL) drew fresh attention after reporting that its investigational antibody ABCL635 met primary efficacy endpoints in a Phase 2 trial for menopausal vasomotor symptoms, with statistically significant benefits versus placebo. See our latest analysis for AbCellera Biologics. Alongside the ABCL635 data, AbCellera Biologics has attracted fresh attention, with a 30 day share price return of 107.07% and a year to date share price return of 250.15%. The 1 year total shareholder...

With the Fed minutes hinting that another rate hike is still on the table and inflation data hovering above the 2% target, short term cash and bond products linked to these decisions are back in the spotlight. This creates potential openings for investors watching short duration yields and money markets. This article first unpacks the backdrop, then walks through three stocks from our U.S. short duration and cash focused screener that appear positively exposed to this news. The stocks covered...

Exponent (EXPO) has caught investor attention after its recent share price move, with the stock up 3.6% over the past week and about 11.5% over the past month based on provided data. See our latest analysis for Exponent. Zooming out, Exponent’s recent 90 day share price return of 22.52% contrasts with a year to date share price move that is roughly flat. The 3 year and 5 year total shareholder returns show declines, which suggests momentum has picked up only in the shorter term as investors...

Green Plains earnings and production update Green Plains (GPRE) recently reported second quarter 2026 results that combined lower sales of US$446.22 million with a move to net income of US$67.15 million from a loss a year earlier. At the same time, the company released unaudited operating data that showed reduced ethanol, distillers grains, ultra high protein and renewable corn oil output compared with the prior year period, along with lower corn consumption. See our latest analysis for Green...

Dividend increase draws attention to Carlisle Companies stock Carlisle Companies (CSL) has drawn investor focus after its board approved a 14% increase in the regular quarterly dividend to $1.25 per share, payable on September 1, 2026. See our latest analysis for Carlisle Companies. Carlisle Companies’ dividend move comes after a period where the share price has shown positive momentum in recent months, with an 11.7% 1 month share price return and a 10.0% 3 month share price return, while the...

In recent days, Eli Lilly announced multiple R&D agreements, including global rights to AlzeCure’s preclinical Alzheimer’s candidate ACD680 with potential milestones above US$1.00 billion, an ion channel collaboration with OmniAb, and a taRNA vaccine partnership with Amplitude Therapeutics, while also securing UK approval of its once-daily oral GLP‑1 drug Foundayo for weight management and type 2 diabetes. These deals and the Foundayo approval deepen Lilly’s presence in obesity,...

Progressive stock has delivered a very strong 152.4% return over the past 5 years. On current checks it now looks closer to fairly priced than clearly cheap or clearly expensive. For investors, the question is how to read that long term gain against valuation signals that point to an “about right” market view. Progressive has returned 152.4% over 5 years, which puts long term holders in a strong position and raises the bar for any further value driven upside. Future underwriting discipline...

Nordson Corporation reported past third-quarter 2026 results, with sales rising to US$817.67 million from US$741.51 million and net income increasing to US$152.85 million from US$125.78 million, alongside higher basic and diluted earnings per share from continuing operations. Over the first nine months of fiscal 2026, Nordson’s sales climbed to US$2.23 billion and net income to US$403.54 million, highlighting earnings growth that may be important when compared with earlier analyst...

ICON (NasdaqGS:ICLR) stock is in focus after ICON Investments Six Designated Activity Company announced a US$2.15b senior unsecured notes offering. The proceeds are aimed at refinancing existing secured borrowings and releasing related collateral and guarantees. See our latest analysis for ICON. The refinancing news lands after a strong 90 day share price return of 47.97%, although the share price return year to date is down 8.58% and the 5 year total shareholder return is down 31.46%. This...

Tradeweb Markets stock has delivered a 22.4% gain over the past three years, yet current valuation checks point to the shares trading at a premium, with both the intrinsic value estimate from the Excess Returns model and traditional multiples suggesting the price is ahead of those fundamentals. Over the last three years, Tradeweb Markets has returned 22.4%, which is a solid result but not obviously in line with a premium valuation. July 2026 trading volumes reached $67.5t, which can support...

EnerSys has delivered a strong 131.2% total return over the past five years, and after the latest rally investors are now weighing whether the recent price near $193.95 still lines up with what intrinsic value and market multiples suggest. Over five years, a 131.2% gain indicates EnerSys has already rewarded long term holders, so fresh capital now needs a clearer margin of safety. Recent profit and margin strength can support higher earnings expectations, while any setback in sustaining...

With tariffs on key Canadian goods briefly delayed and a tentative U.S.-Canada trade deal on the table, cross border exporters suddenly look very different to earlier this week. This pause in trade shock risk, plus a stronger Canadian dollar, could reshape which stocks feel pressure and which look better placed. This article walks through three stocks exposed to this news and why their stories now deserve closer attention. The stocks discussed below are just a starting sample, and the full...

Investors came into this Prenetics Global earnings print betting on a high growth healthcare stock that screens as deeply undervalued on some fair value models. The immediate verdict in the market told a cooler story. The stock slipped about 3.3% to US$18.76, even as the quarter showed sharply narrower losses and a much higher revenue base than earlier periods. The headline is simple. Prenetics Global is still loss making, with basic earnings per share of roughly US$0.53 in the red for Q2,...